letibotulinumtoxina
Trade name: Letybo
Small moleculeapproved
Approved
Feb 29, 2024
Clinical trial activity
1 trials · 1 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Jun 14, 2022 (NCT07072806)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Synaptosomal-associated protein 25HYDROLYTIC ENZYME
Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
- Botulinum neurotoxin type GSupplementation
botG supplementation
Approval history
- approvedFeb 29, 2024
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707322 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07072806 | Phase 4 | Jun 14, 2022 | Yonsei University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Hugel | For profit | NDA | Feb 29, 2024 |